SANDOZ INC

Alembic Nelarabine injection gets FDA final approval

Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in adult and pediatric patients. The approved drug is therapeutically equivalent to Arranon Injection, 250 mg/50 mL (5 mg/mL), of Sandoz Inc.